News
NWBO
0.175
+6.00%
0.010
Northwest Biotherapeutics says UK regulator has not rejected DCVax-L glioblastoma filing
PUBT · 20h ago
Weekly Report: what happened at NWBO last week (0713-0717)?
Weekly Report · 21h ago
First Berlin reiterates Buy on Northwest Biotherapeutics, keeps USD 1 price target
PUBT · 07/13 13:22
Weekly Report: what happened at NWBO last week (0706-0710)?
Weekly Report · 07/13 09:40
Northwest Biotherapeutics's Newest Presentation Does Not De-Risk The Thesis, But The Story Is Not Over Yet
Seeking Alpha · 07/08 21:30
Northwest Bio says updated IPD analyses show DCVax-L extends glioblastoma survival more than prior Phase III readout
PUBT · 07/08 18:25
NORTHWEST BIOTHERAPEUTICS PRESENTS UPDATED SURVIVAL DATA FROM PHASE III TRIAL OF DCVAX®-L FOR GLIOBLASTOMA USING INDIVIDUAL PATIENT LEVEL DATA IN MULTIPLE INDEPENDENT ANALYSES
Reuters · 07/08 18:24
Weekly Report: what happened at NWBO last week (0629-0703)?
Weekly Report · 07/06 09:42
Northwest Biotherapeutics issues press release on BNOS presentation covering DCVax-L propensity score matching analysis
PUBT · 07/02 18:19
Northwest Bio to present propensity score matching analysis linking DCVax-L to survival at BNOS meeting
PUBT · 07/02 18:18
Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting
PR Newswire · 07/02 18:17
Weekly Report: what happened at NWBO last week (0622-0626)?
Weekly Report · 06/29 09:39
Weekly Report: what happened at NWBO last week (0615-0619)?
Weekly Report · 06/22 09:44
Weekly Report: what happened at NWBO last week (0608-0612)?
Weekly Report · 06/15 09:45
Weekly Report: what happened at NWBO last week (0601-0605)?
Weekly Report · 06/08 09:42
Weekly Report: what happened at NWBO last week (0525-0529)?
Weekly Report · 06/01 09:45
First Berlin reiterates Buy on Northwest Biotherapeutics, keeps USD 1 price target
PUBT · 05/28 11:43
Weekly Report: what happened at NWBO last week (0518-0522)?
Weekly Report · 05/25 09:47
Weekly Report: what happened at NWBO last week (0511-0515)?
Weekly Report · 05/18 09:46
Northwest Bio narrows Q1 net loss to $3.1 million
PUBT · 05/15 20:42
More
Webull provides a variety of real-time NWBO stock news. You can receive the latest news about Northwest Bio through multiple platforms. This information may help you make smarter investment decisions.
About NWBO
Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and includes treatment of a diverse range of more than a dozen types of cancers. Its subsidiaries include Flaskworks LLC, NW Bio GmbH, Northwest Biotherapeutics Capital Limited, Northwest Biotherapeutics B.V., Advent BioServices Ltd., and others.